NASDAQ:ETHZ

Flag Ship Acquisition Q2 2024 Earnings Report

Flag Ship Acquisition logo
$5.03 -0.13 (-2.52%)
As of 06/23/2026

Flag Ship Acquisition EPS Results

Actual EPS
$0.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Flag Ship Acquisition Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Flag Ship Acquisition Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Flag Ship Acquisition Earnings Headlines

Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
See More Flag Ship Acquisition Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Flag Ship Acquisition? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Flag Ship Acquisition and other key companies, straight to your email.

About Flag Ship Acquisition

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

View Flag Ship Acquisition Profile